New study aims to unlock the secrets of Children's rare blood diseases
NCT ID NCT04070612
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows children in France diagnosed with severe autoimmune cytopenia—conditions where the immune system attacks blood cells. Researchers will track their health over time to see who achieves remission and what factors influence their recovery. The goal is to better understand how these diseases progress and improve future care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this research could identify factors that predict remission, helping doctors tailor treatments for children with these blood disorders.
- What could go wrong
- This is an observational study, not a treatment trial. It will not test new therapies, and findings may not lead to immediate changes in care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE HAEMOLYTIC ANAEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells take aim at stubborn blood disorder
- Cheap drug combo may tame tough anemia
- Scientists hunt for genetic roots of rare childhood blood disorder
- New hope for rare bleeding disorder: experimental drug JCXH-213 enters human trials
- Experimental CAR-T therapy takes on stubborn blood disorder
- Can a cancer drug stop a blood disorder before it turns deadly?